Despite advances in our understanding of the pathophysiology of PD, recent research have shown that the Nrf2 (NF-E2-related factor 2)/antioxidant responsive element (ARE) signaling cascade is the most potential target for therapeutic treatment [5]. This evidence concerns the gene NFE2L2 and Parkinson disease.